Global Cord Stem Cell Banking Market – Industry Trends and Forecast to 2024 | Data Bridge Market Research - Data Bridge Market Research

SUBSCRIBE FOR UPDATED REPORTS

Get great contents delivered straight to your inbox everyday, just a click away, Sign Up Now.
Name
Email

Global Cord Stem Cell Banking Market – Industry Trends and Forecast to 2024

Reports

Global Cord Stem Cell Banking Market, By Storage Type (Private Banking, Public Banking), By Product Type (Cord Blood, Cord Blood & Cord Tissue), By Service Type (Collection & Transportation, Processing, Analysis, Storage), By Source (Umbilical Cord Blood, Bone Marrow, Peripheral Blood Stem, Menstrual Blood), By Indication (Cerebral Palsy, Thalassemia, Leukemia, Diabetes, Autism), By Geography (North America, Europe, Asia-Pacific, South America, Rest of the World) –  Industry Trends and Forecast to 2024

$4,200.00
Clear selection

Global cord stem cell banking market is expected to reach USD 9.44 billion by 2022 from USD 1.84 billion in 2016, at a CAGR of 22.4% in the forecast period 2017 to 2024. The new market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.

In 2016, an estimated 940.3 thousand cord cells and tissues were banked globally, which is expected to grow at a CAGR of 14.7% in the forecast period 2016 to 2022 reaching 2,141.1 thousand by 2022. An increased awareness of application of cord stem cells in therapeutics is expected to fuel the growth of this market in major and emerging economies.

Based on product type the market is segmented into cord blood and cord blood & cord tissues. In 2016 the market is dominated by the cord blood segment with 63.7% market share in terms of value and is also expected to grow at the highest CAGR of 24.7% in the forecast period 2017 to 2024.

Cord blood is the blood remaining in the vein of the umbilical cord at the time of birth and happens to be a good source for hematopoietic stem cells as opposed to cord tissue known for mesenchymal stem cells. The banking of cord blood has gained momentum over the past 7-8 years as the awareness regarding its use in stem cell based therapeutics has increased. Cord blood is easy to isolate in a painless and harm free procedure and is free from graft-versus-host infections and viral infections along with high rate of engraftment. It makes umbilical cord blood one of the most economical sources of hematopoietic stem cells useful for treating various blood related disorders. Both private and public banks preserve cord blood for a period of over 25 years and release many units for the purpose of clinical trials. Cord blood is being used to treat over 80 different types of blood related diseases successfully, such as leukemia, thalassemia, autoimmune diseases, and inherited metabolic disorders, to name a few. Clinical trials are on an increase for various other blood related disorders such as hemophilia, hereditary spherocytosis, cerebral palsy, and others with the potential for future use holding great promise.

Cord tissue is the tissue of the umbilical cord that contains blood vessels supported by a tissue called Wharton’s jelly that happens to be a rich source of mesenchymal stem cells. The mesenchymal stem cells are multipotent in nature, having the ability to proliferate and differentiate into muscle, cartilage, bone, and fat cells. Mesenchymal stem cells thus have the potential to treat a number of diseases and conditions long thought to be incurable and thus revolutionize the medical field. Research indicates that the cord tissue will help treat diseases or conditions of the cartilage, muscles, and nerve cells and over 50 diseases are under clinical trials. Not all stem cells banks offer the storage of cord tissue, but with the advent of MSCs in therapeutics, many banks are availing this facility. Cord tissue is known to work specifically towards spinal and brain injuries. Clinical trials are currently underway for diseases such as multiple sclerosis, cartilage repair, stroke, brain damage, liver cirrhosis, traumatic optic neuropathy, muscular dystrophy, and many such others. These cells, still under the clinical trial phase, are said to have the potential to treat various diseases such as heart disease, Parkinson’s disease, type 1 diabetes, injuries to bones and cartilage, and lung cancer along with many others. It is also being tested in the use of various skin disorders such as psoriasis, eczema, and so on. Cord tissue stem cells have the important characteristic of multipotency, making them capable to treat a vast number of diseases in comparison to those that cord blood alone can treat.

On the basis of storage type the global cord stem cell banking market is segmented into public and private storage. In 2016, the public stem cell banks is expected to dominate the market in terms of market volume storage though the private banks is expected to dominate in terms of value. This is owing to the public stem cell banks not charging the customers for storage of stem cell but only charging for extraction which is done by third party agencies.

On the basis of service type the global cord stem cell banking market is segmented into collection & transportation, processing, analysis and storage. In 2016, the processing segment is expected to dominate the market with 47.3% market share and is expected to grow at a CAGR of 19.3% in the forecast period. The collection and transportation segment is expected to grow at the highest CAGR of 22.3% in the forecast period. However the services may vary very differently across countries owing to private banks charging very differently in different countries.

Based on Indication the market is segmented into cerebral palsy, thalassemia, autism, type 1 diabetes, anemia, leukemia, and others. Cerebral Palsy (CP) is most commonly described as the loss or impairment of motor skills. The research on treatment of CP with stem cells is in its preliminary stage, while the research on mesenchymal cells has shown a positive effect. Mesenchymal cells can’t develop into brain cells. However, they help to protect damaged cells and prolong their survival by releasing substances that help in the recovery of cells. Though there are 819.8 thousand samples stored still only approximately 8000 units were used. In 2016, cerebral palsy is expected to dominate the market with 24.7% market share.

On the basis of source the global cord stem cell banking market is segmented into umbilical cord blood, bone marrow, peripheral blood stem and menstrual blood. Among these, umbilical cord is the most preferred source, owing to the high multiplication capability of the umbilical cord stem cells and lesser rejection rate during transplantation. Furthermore, this method of extraction is noninvasive, and the stem cells are not affected by environment contamination.

Based on geography the market is segmented into 5 geographical regions, North America, Europe, Asia-Pacific, South America and rest of the world. The geographical regions are further segmented into 24 major countries such as U.S. Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Belgium, Turkey, Japan, China, Singapore, Brazil, India, Russia, South Africa and many others. North America is expected to dominate the market with 43.7% market share in 2016. This market is mainly driven by the increasing number of parents storing their child’s cord blood.

The report also includes company share analysis for the major companies operating in this market by major regions North America, Europe and Asia Pacific. The details of mergers & acquisitions, product launches, expansions, and product life cycle matrix is also a part of this report. Some of the major players operating in the global cord stem cell banking market are CBR Systems, Inc., Cordlife, CryoCell, Cryo-Save AG, Lifecell, Stemcyte, Viacord, Smart Cells International, Ltd., Cryoviva India and China Cord Blood Corporation among others.

Share this!
Choose Licence Type

Enterprise, Single User

1.  INTRODUCTION

        1.1.      OVERVIEW OF THE CORD STEM CELL BANKING MARKET
        1.2.      MARKET SEGMENTATION & COVERAGE
                         1.2.1. CURRENCY AND PRICING
                         1.2.2. LIMITATION

2. RESEARCH METHODOLOGY

        2.1.      KEY TAKEAWAYS
        2.2.      ARRIVING AT THE CORD STEM CELL BANKING MARKET SIZE
                         2.2.1. MARKET CRACKDOWN APPROACH
                         2.2.2. COMPANY REVENUE AND MARKET SHARE ANALYSIS
                         2.2.3. DATA TRIANGULATION
                         2.2.4. KEY DATA POINTS FROM PRIMARY SOURCES
                         2.2.5. KEY DATA POINTS FROM SECONDARY SOURCES
                         2.2.6. PORTER’S FIVE FORCES MATRIX
                         2.2.7. PEST ANALYSIS
        2.4.      GLOBAL CORD STEM CELL BANKING MARKET: RESEARCH SNAPSHOT
        2.3.      ASSUMPTIONS

3. MARKET LANDSCAPE SUMMARY

4. PREMIUM INSIGHTS

        4.1.      OVERVIEW
        4.2.      CORD STEM CELL BANKING MARKET: KEY PRIMARY INSIGHTS
        4.3.      MARKET OVERVIEW
                         4.3.1. DRIVERS
                               4.3.1.1.     EASY EXTRACTION METHODS
                               4.3.1.2.     RISING NUMBER OF NEWBORNS
                               4.3.1.3.     INCREASED ACCEPTANCE OF STEM CELL THERAPEUTICS
                               4.3.1.4.     NEW APPLICATIONS OF STEM CELLS IN DISEASE TREATMENT
                         4.3.2. RESTRAINTS
                               4.3.2.1.     LACK OF AWARENESS IN MANY DEVELOPING ECONOMIES
                               4.3.2.2.     CONSTRAINING LEGAL AND HEALTHCARE REGULATIONS
                               4.3.2.3.     HIGH OPERATING COST OF STEM CELL THERAPEUTICS
                        4.3.3. OPPORTUNITIES
                               4.3.2.1.     RISING AWARENESS ABOUT USAGE OF CORD TISSUE
                               4.3.2.2.     CORD BLOOD BANKS COLLABORATIONS
                               4.3.2.3.     INCREASED TECHNOLOGICAL DEVELOPMENT
                        4.3.4. THREATS
        4.4.      KEY MARKET FINDINGS
        4.5.      KEY MARKET TRENDS AND UPCOMING TECHNOLOGIES

5. CORD STEM CELL BANKING MARKET, BY STORAGE TYPE

        5.1.      OVERVIEW
        5.2.     PUBLIC CORD STEM CELL BANKING
                       5.2.1. MARKET VALUE, 2014 TO 2022
                       5.2.2. NUMBER OF UNITS STORED, 2014 TO 2022
                       5.2.3. MARKET TRENDS AND FORECAST INSIGHTS
        5.3.      PRIVATE CORD STEM CELL BANKING
                       5.3.1. MARKET VALUE, 2014 TO 2022
                       5.3.2. NUMBER OF UNITS STORED, 2014 TO 2022
                       5.3.3. MARKET TRENDS AND FORECAST INSIGHTS
        5.4.     COMPARISON MATRIX: PUBLIC VS PRIVATE CORD STEM CELL BANKING

6. CORD STEM CELL BANKING MARKET, BY PRODUCT TYPE

        6.1.      OVERVIEW
        6.2.      CORD BLOOD
                       6.2.1. MARKET VALUE, 2014 TO 2022
                       6.2.2. NUMBER OF UNITS STORED, 2014 TO 2022
                       6.2.3. MARKET TRENDS AND FORECAST INSIGHTS
        6.3.      CORD TISSUE AND CORD BLOOD
                       6.3.1. MARKET VALUE, 2014 TO 2022
                       6.3.2. NUMBER OF UNITS STORED, 2014 TO 2022
                       6.3.3. MARKET TRENDS AND FORECAST INSIGHTS

7. CORD STEM CELL BANKING MARKET, BY SERVICE TYPE

        7.1.       OVERVIEW
        7.2.      COLLECTION & TRANSPORTATION
        7.3.      ANALYSIS
        7.4.      PROCESSING
        7.5.      STORAGE

8. CORD STEM CELL BANKING MARKET, BY SOURCE TYPE

        8.1.      OVERVIEW
        8.2.      UMBILICAL CORD BLOOD
        8.3.      BONE MARROW
        8.4.     PERIPHERAL BLOOD STEM
        8.5.      MENSTRUAL BLOOD

9. CORD STEM CELL BANKING MARKET, BY SOURCE TYPE

        9.1.      OVERVIEW
        9.2.      CEREBRAL PALSY
                       9.2.1. MARKET VALUE, 2014 TO 2022
                       9.2.2. NUMBER OF UNITS USED, 2014 TO 2022
                       9.2.3. MARKET TRENDS AND FORECAST INSIGHTS
        9.3.      THALASSEMIA
                       9.3.1. MARKET VALUE, 2014 TO 2022
                       9.3.2. NUMBER OF UNITS USED, 2014 TO 2022
                       9.3.3. MARKET TRENDS AND FORECAST INSIGHTS
        9.4.      LEUKEMIA
                       9.4.1. MARKET VALUE, 2014 TO 2022
                       9.4.2. NUMBER OF UNITS USED, 2014 TO 2022
                       9.4.3. MARKET TRENDS AND FORECAST INSIGHTS
        9.5.       DIABETES
                       9.5.1. MARKET VALUE, 2014 TO 2022
                       9.5.2. NUMBER OF UNITS USED, 2014 TO 2022
                       9.5.3. MARKET TRENDS AND FORECAST INSIGHTS
        9.6.      AUTISM
                       9.6.1. MARKET VALUE, 2014 TO 2022
                       9.6.2. NUMBER OF UNITS USED, 2014 TO 2022
                       9.6.3. MARKET TRENDS AND FORECAST INSIGHTS
        9.7.       OTHERS
                       9.7.1. MARKET VALUE, 2014 TO 2022
                       9.7.2. NUMBER OF UNITS USED, 2014 TO 2022
                       9.7.3. MARKET TRENDS AND FORECAST INSIGHTS

10. CORD STEM CELL BANKING MARKET, BY GEOGRAPHY

        10.1.     COUNTRYWISE CORD STEM CELL BANKING MARKET, (VALUE AND VOLUME)
                       10.1.1.      NORTH AMERICA
                                        10.1.1.1.      U.S.
                                        10.1.1.2.      CANADA
                                        10.1.1.3.      MEXICO
                       10.1.2.     EUROPE
                                        10.1.2.1.      GERMANY
                                        10.1.2.2.      FRANCE
                                        10.1.2.3.      U.K.
                                        10.1.2.4.      ITALY
                                        10.1.2.5.      SPAIN
                                        10.1.2.6.      RUSSIA
                                        10.1.2.7.      TURKEY
                                        10.1.2.8.      BELGIUM
                                        10.1.2.9.      NETHERLANDS
                                        10.1.2.10.      SWITZERLAND
                                        10.1.2.11.    REST OF EUROPE
                       10.1.3.      ASIA-PACIFIC (APAC)
                                        10.1.3.1.      JAPAN
                                        10.1.3.2.      CHINA
                                        10.1.3.3.      SOUTH KOREA
                                        10.1.3.4.      INDIA
                                        10.1.3.5.      AUSTRALIA
                                        10.1.3.6.      SINGAPORE
                                        10.1.3.7.      THAILAND
                                        10.1.3.8.      MALAYSIA
                                        10.1.3.9.      INDONESIA
                                        10.1.3.10.      PHILIPPINES
                                        10.1.3.11.      REST OF APAC
                       10.1.4.    LATIN AMERICA
                                        10.1.4.1.     BRAZIL
                                        10.1.4.2.     REST OF LATIN AMERICA
                       10.1.5.    MIDDLE EAST AND AFRICA
                                        10.1.5.1.     SOUTH AFRICA
                                        10.1.5.2.     REST OF MIDDLE EAST AND AFRICA
        10.2.     KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES

11. CORD STEM CELL BANKING MARKET: COMPETITIVE LANDSCAPE

        11.1.     GLOBAL CORD STEM CELL BANKING MARKET: COMPANY SHARE ANALYSIS
        11.2.     NORTH AMERICA CORD STEM CELL BANKING MARKET: COMPANY SHARE ANALYSIS
        11.3.     EUROPE CORD STEM CELL BANKING MARKET: COMPANY SHARE ANALYSIS
        11.4.    APAC CORD STEM CELL BANKING MARKET: COMPANY SHARE ANALYSIS
        11.5.    MERGERS & ACQUISITIONS
        11.6.    NEW PRODUCT DEVELOPMENT & APPROVALS
        11.7.     EXPANSIONS
        11.8.    REGULATORY CHANGES
        11.9.    PATENTS
        11.10.  PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

12. CORD STEM CELL BANKING MARKET, COMPANY PROFILES

        12.1     CBR SYSTEMS, INC.
                     12.1.1   OVERVIEW
                     12.1.2   SWOT ANALYSIS
                     12.1.3   PRODUCT PORTFOLIO
                     12.1.4   REVENUE ANALYSIS
                     12.1.5   ANALYSTS VIEW
        12.2    CORDLIFE
                     12.2.1   OVERVIEW
                     12.2.2   SWOT ANALYSIS
                     12.2.3   PRODUCT PORTFOLIO
                     12.2.4   REVENUE ANALYSIS
                     12.2.5   ANALYSTS VIEW
        12.3    CRYOCELL
                     12.3.1   OVERVIEW
                     12.3.2   SWOT ANALYSIS
                     12.3.3   PRODUCT PORTFOLIO
                     12.3.4   REVENUE ANALYSIS
                     12.3.5   ANALYST VIEW
        12.4    CRYO-SAVE AG
                     12.4.1   OVERVIEW
                     12.4.2   SWOT ANALYSIS
                     12.4.3   PRODUCT PORTFOLIO
                     12.4.4   REVENUE ANALYSIS
                     12.4.5   ANALYSTS VIEW
        12.5    LIFECELL
                     12.5.1   OVERVIEW
                     12.5.2   SWOT ANALYSIS
                     12.5.3   PRODUCT PORTFOLIO
                     12.5.4   REVENUE ANALYSIS
                     12.5.5   ANALYSTS VIEW
        12.6    STEMCYTE
                     12.6.1   OVERVIEW
                     12.6.2   SWOT ANALYSIS
                     12.6.3   PRODUCT PORTFOLIO
                     12.6.4   REVENUE ANALYSIS
                     12.6.5   ANALYSTS VIEW
        12.7    SMART CELLS INTERNATIONAL, LTD.
                     12.7.1   OVERVIEW
                     12.7.2   SWOT ANALYSIS
                     12.7.3   PRODUCT PORTFOLIO
                     12.7.4   REVENUE ANALYSIS
                     12.7.5   ANALYSTS VIEW
        12.8   CRYOVIVA INDIA
                     12.8.1   OVERVIEW
                     12.8.2   SWOT ANALYSIS
                     12.8.3   PRODUCT PORTFOLIO
                     12.8.4   REVENUE ANALYSIS
                     12.8.5   ANALYSTS VIEW
        12.9   CHINA CORD BLOOD CORPORATION
                     12.9.1   OVERVIEW
                     12.9.2   SWOT ANALYSIS
                     12.9.3   PRODUCT PORTFOLIO
                     12.9.4   REVENUE ANALYSIS
                     12.9.5   ANALYSTS VIEW
        12.10 CRYOVIDA
                     12.10.1   OVERVIEW
                     12.10.2   SWOT ANALYSIS
                     12.10.3   PRODUCT PORTFOLIO
                     12.10.4   REVENUE ANALYSIS
                     12.10.5   ANALYSTS VIEW
        12.11  VIACORD
                     12.11.1   OVERVIEW
                     12.11.2   SWOT ANALYSIS
                     12.11.3   PRODUCT PORTFOLIO
                     12.11.4   REVENUE ANALYSIS
                     12.11.5   ANALYSTS VIEW

13. APPENDIX

        13.1    RELATED REPORTS
        13.2    CUSTOMIZABLE OPTIONS
        13.3    SOURCE SHEET
        13.3    BIBLIOGRAPHY

14. ABOUT DATA BRIDGE MARKET RESEARCH

 

 

Share this!

Thank You

Share this!

Please fill in the below form and our sales representatives will get back to you.

Thank You

Share this!
`
Show Buttons
Hide Buttons